What is the recommended initial treatment and management plan for sarcoidosis with symptomatic pulmonary or ocular involvement, including prednisone dosing, tapering schedule, baseline laboratory monitoring, and steroid-sparing agents?

Initial Treatment for Symptomatic Pulmonary or Ocular Sarcoidosis

For symptomatic pulmonary sarcoidosis, start with oral prednisone 20-40 mg daily (or consider methotrexate as a first-line alternative), taper over 6-18 months based on response, and add steroid-sparing agents if unable to taper below 10 mg daily or if significant adverse effects occur. 1, 2, 3

Prednisone Dosing and Tapering

Initial Dosing

• Start with 20-40 mg oral prednisone daily 1, 2, 4
• Recent evidence shows 20 mg daily is non-inferior to 40 mg daily for pulmonary sarcoidosis, with similar efficacy and adverse effect profiles 5
• Administer in the morning (before 9 AM) to minimize HPA axis suppression 2
• Continue initial dose for 2-6 weeks until satisfactory clinical response 2, 4

Tapering Schedule

• Taper gradually over 6-18 months if symptoms, pulmonary function tests, and radiographs improve 2, 4
• Decrease in small increments at appropriate intervals to reach the lowest effective maintenance dose 2
• Target maintenance dose: ≤10 mg daily prednisone - inability to taper below this threshold indicates need for steroid-sparing agents 6, 4
• Never stop abruptly - gradual withdrawal is essential to prevent adrenal insufficiency 2

Methotrexate as First-Line Alternative

The 2025 PREDMETH trial demonstrated methotrexate is non-inferior to prednisone as first-line therapy for pulmonary sarcoidosis 3. This represents a paradigm shift:

• Methotrexate showed equivalent improvement in FVC (6.11 percentage points vs 6.75 for prednisone) at 24 weeks 3
• Different side-effect profile: methotrexate causes nausea, fatigue, and liver function abnormalities; prednisone causes weight gain, insomnia, and increased appetite 3
• Consider methotrexate first-line when patients have contraindications to corticosteroids or strong preference to avoid steroid side effects 3

Ocular Sarcoidosis Treatment

For symptomatic ocular involvement, glucocorticoids are strongly recommended 1:

• Oral prednisone using similar dosing as pulmonary disease 1
• All patients with sarcoidosis require baseline ophthalmology examination regardless of symptoms, as 20-40% have ocular involvement and some cases are asymptomatic 7
• Repeat eye exams based on new symptoms in those initially without involvement 7
• Treatment prevents vision loss, which is irreversible if not addressed 7

Baseline Laboratory Monitoring

Before initiating treatment, obtain:

• Serum creatinine - sarcoidosis causes renal dysfunction through granulomatous inflammation and hypercalcemia-related mechanisms; ~90% improve with immunosuppression 7
• Liver function tests (especially if considering methotrexate)
• Complete blood count
• Calcium levels (hypercalcemia occurs in sarcoidosis)
• Pulmonary function tests (FVC as primary monitoring parameter)
• Chest imaging

Steroid-Sparing Agents

When to Add Second-Line Agents

Add steroid-sparing therapy when:

• Unable to taper prednisone below 10 mg daily 6, 4
• Significant corticosteroid-related adverse effects occur 4
• Disease progression despite adequate corticosteroid therapy 1

First Choice: Methotrexate

Methotrexate is the preferred second-line agent by expert consensus 1, 6:

• Typical dosing: once weekly for at least 2 years 8
• Enables corticosteroid discontinuation in most patients 8
• For neurosarcoidosis specifically, add methotrexate if glucocorticoids alone are insufficient 1

Alternative Second-Line Agents

• Azathioprine - effective as corticosteroid-sparing agent 8
• Mycophenolate mofetil - option for refractory cases 1
• Consider these when methotrexate is contraindicated or not tolerated

Third-Line: Anti-TNF Therapy

Infliximab is recommended for refractory disease 1:

• Add when glucocorticoids plus second-line agent (methotrexate, azathioprine, or mycophenolate) fail to control disease 1
• Conditional recommendation for pulmonary, cutaneous, and neurosarcoidosis 1
• Requires appropriate microbial prophylaxis for Pneumocystis jiroveci and herpes zoster 4

Critical Monitoring Parameters

• FVC is the primary outcome measure for pulmonary disease 3, 4
• Serial pulmonary function tests every 3-6 months during treatment
• Chest imaging to assess radiographic response
• Screen for pulmonary hypertension in advanced disease (present in up to 70% of advanced cases, 5-year mortality ~40%) 4

Common Pitfalls to Avoid

1. Starting with excessive corticosteroid doses - 20 mg is as effective as 40 mg with similar side effects 5
2. Tapering too rapidly - increases relapse risk; taper over 6-18 months 2
3. Delaying steroid-sparing agents - add when unable to taper below 10 mg daily rather than continuing high-dose steroids 6
4. Missing ocular involvement - always perform baseline ophthalmology exam even without symptoms 7
5. Ignoring renal screening - check creatinine at baseline as renal involvement is treatable 7